Article Text

COPD exacerbations · 5: Management
Free
  1. R Rodríguez-Roisin
  1. Correspondence to:
    Professor R Rodríguez-Roisin
    Servei de Pneumologia, Hospital Clínic, Villarroel 170, 08036 Barcelona, Spain; rororo{at}clinic.ub.es

Abstract

A review of the most relevant evidence based therapeutic options currently available for the management of exacerbations of COPD

  • COPD, chronic obstructive pulmonary disease
  • CRP, C-reactive protein
  • FEV1, forced expiratory volume in 1 second
  • LABA, long acting inhaled β2 agonist
  • LABD, long acting bronchodilator
  • MDI, metered dose inhaler
  • NIV, non-invasive ventilation
  • PEFR, peak expiratory flow rate
  • SABA, short acting β2 agonist
  • SABD, short acting bronchodilator
  • SAMA, short acting muscarinic antagonist
  • Sao2, arterial oxygen saturation
  • chronic obstructive pulmonary disease
  • exacerbations
  • management
View Full Text

Statistics from Altmetric.com

Supplementary materials

  • Files in this Data Supplement:

    • view PDF - Supplemental tables 1-3 and supplemental figure 1.

Footnotes

  • Supported by the Red Respira-ISCIII-RTIC-03/11 and the Comissionat per a Universitats i Recerca de la Generalitat de Catalunya (2005 SGR-00822). Dr R R-R holds a career scientist award (2001-07) from the Generalitat de Catalunya.

  • Competing interests: The author has participated as a lecturer and speaker in scientific meetings and courses under the sponsorship of Almirall, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Laboratorios Dr Esteve SA and Pfizer; consulted with several pharmaceutical companies with relevance to the topics discussed in the present article (Almirall, Altana, AstraZeneca, Aventis, Boehringer Ingelheim, GlaxoSmithKline, Laboratorios Dr Esteve SA, Novartis, Pfizer, Viechi and Zambon); serves on advisory boards for Almirall, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pfizer, Procter & Gamble and Viechi; has been sponsored for several clinical trials; and has received laboratory research support from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Laboratorios Dr Esteve SA, Pfizer and Procter & Gamble Ltd.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.